MSManush Sondhi

Manush Sondhi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manush Sondhi has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Financial toxicity among US adults with rheumatic disease and prior cancer: a nationally representative cross-sectional study

    by Manush Sondhi, Bhavik Bansal, Hemant Khandelia, Jiha Lee, Sebastian E. Sattui, Siddharth Singh, Namrata Singh

    Objective Financial toxicity (FT), the financial burden of accessing health care, is well known in oncology care and increasingly seen in rheumatic disease (RD). We compared FT among adults with neither condition, RD only, cancer only, and both. Methods We used data from the National Health Interview Survey, a nationally representative sample of US adults from 2019 to 2023. Adults were categorized by self-reported diagnosis of a RD, including arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia, and cancer. FT was defined as one or more of the following: financial distress, difficulty paying bills, delayed or forgone care, cost related medication nonadherence, or food insecurity. Weighted logistic regressions examined associations between disease groups and FT, adjusting for demographics, comorbidities, and insurance. Analyses were stratified by age (< 65 versus ≥ 65 years). Results Among 149,905 adults, 100,652 had neither condition, 10,094 had cancer only, 30,446 had RD only, and 8,713 had both. Those with both conditions were older and had the highest multimorbidity. Among adults < 65 years, FT was highest in RD only and both groups (63.9% and 64.3%) vs neither (54.0%). Cost-related medication nonadherence was more common in RD. Among adults ≥ 65 years, FT remained highest in RD only (41.4%). In adjusted analyses, RD only and both conditions were associated with increased FT, whereas cancer only was not. Conclusion RD is associated with substantial financial burden across domains. These findings highlight the need for greater recognition of financial toxicity in rheumatology. Key Points • This study provides the first nationally representative analysis to characterize and directly compare financial toxicity across adults with rheumatic disease (RD) only, cancer only, and the co-occurrence of both conditions. • Living with a RD is a primary and persistent driver of financial hardship across all adult age groups, extending the financial toxicity literature beyond its traditional focus on oncology. • These findings highlight an under-recognized burden in rheumatology and underscore the need for greater attention to identifying and addressing financial hardship in this population.

  • A Compelling Medley of Maladies

    by Manush Sondhi, Warda Maqsood, Tarun Selvarajan, Alexandre Malek, Sarwat Umer

  • A Conundrum in Coexistence

    by Manush Sondhi, Samina Hayat

  • Open Access

    Management of Hepatic Sarcoidosis: A Retrospective Analysis of Patients at a University Hospital

    by Manush Sondhi, Sulman Hasan, Kavya Vadlamudi, Mohammad Alfrad Nobel Bhuiyan, Anusheh Ali, Tabitha Muutu, Samina Hayat, Sarwat Umer, Kinza Muzaffar

    Objective: To explore efficacy of medications, namely steroids, ursodeoxycholic acid (UDC), methotrexate (MTX), azathioprine, mycophenolate mofetil (MMF), and infliximab in the treatment of hepatic sarcoidosis (HS). Methods: We searched for the patients using ICD codes for sarcoidosis (ICD-10: D86) and granulomatous hepatitis (ICD-10: K75.3) at Louisiana State University, Shreveport, and generated 150 unique medical record numbers. We retrospectively reviewed notes, labs, imaging, and medications, and used descriptive statistics to calculate percentages. Results: 47 patients had a diagnosis of HS. 72% of patients had ALP elevation of >200. 36 (76%) patients received steroids, 20 (42%) had MTX, 5 (10%) had azathioprine, 5 (10%) had rituximab, 12 (25%) had infliximab, 3 (6%) had UDC, 21 (44%) had MMF. 12 patients received a combination of prednisone with either MTX, azathioprine, MMF, infliximab, or rituximab. Treatment response was measured based on ALP improvement. 55% of patients responded to prednisone, 45% to MTX, 40% to azathioprine, 60% to rituximab, 66% to infliximab, 47% to MMF, and 30% to UDC. Conclusion: Majority of the patients presented with ALP elevation of >200. Liver biopsy was performed in only 27% of the patients. Despite being one of the recommended initial therapies, UDC was used in only 3% of patients. Steroids were most commonly used. Among all the steroid-sparing agents, infliximab showed the best efficacy. Similarly, MTX showed improvement, but it was generally avoided due to the risk of hepatotoxicity. Azathioprine, MMF, and rituximab were used either in combination or as sole therapies and have shown improvement in ALP. Cite this article as: Sondhi M, Hasan S, Vadlamudi K, Bhuiyan MAN, Ali A, Muutu T, Hayat S, Umer S, Muzaffar K. Management of Hepatic Sarcoidosis: A Retrospective Analysis of Patients at a University Hospital. Mediterr J Rheumatol 2025;36(3):423-427. Article Submitted: 11 Nov 2024; Revised Form: 3 Apr 2025; Article Accepted: 23 Apr 2025; Available Online: 17 Jul 2025 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2025 The Author(s). https://doi.org/10.31138/mjr.111124.thr


  • Open Access

    A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade

    by Manush Sondhi, Megan Lear, Saleha Dar, Madiha Tariq

    Dermatomyositis is a chronic inflammatory condition affecting muscles and skin, often associated with an increased risk of cancer. Specific autoantibodies, including anti-TIF1 (Transcription Intermediary Factor 1), have been linked to this risk. We present a case of dermatomyositis in a male patient positive for anti-TIF1 antibodies, subsequently diagnosed with squamous cell carcinoma of the tonsil, a novel association not previously documented. Early recognition of such associations is crucial for timely intervention and improved outcomes in these patients. A 53-year-old Caucasian male with hyperlipidemia presented with chronic dry, scaly skin and pruritus, diagnosed with eczematous dermatitis. Despite treatment, symptoms persisted. After two years, he reported increased redness of the rash and new eruptions on his hands and fingers. During a rheumatology visit, he reported weight loss, fatigue, muscle weakness, and trismus. Further evaluation indicated signs of dermatomyositis, and laboratory tests revealed anti-TIF1 antibodies, prompting further investigation. The patient underwent age-appropriate cancer screening, and due to a known association with malignancy, a positron emission scan was ordered, detecting increased activity in the right tonsil. Subsequent magnetic resonance imaging showed a suspicious mass in the tonsillar area. A biopsy confirmed invasive squamous cell carcinoma positive for P16+. Initial treatment included radiotherapy, with a post-treatment PET scan showing no evidence of disease. However, four months later, the cancer recurred, leading to significant symptoms and complications. Despite supportive measures, the patient succumbed to high-volume oral cavity bleeding during hospitalization. TIF1 dermatomyositis is a unique subset of dermatomyositis with a strong association with malignancy, particularly squamous cell carcinoma (SCC). Mechanisms connecting TIF1 dermatomyositis and cancer involve gene expression dysregulation and chronic inflammation. Anti-TIF1 antibodies are key biomarkers, with IgG2 isotype levels highly predictive of cancer risk. Common malignancies include ovarian, breast, and lung cancers, often detected within three years of dermatomyositis onset. Distinctive features include severe skin lesions, dysphagia, and minimal interstitial lung disease. Management focuses on early cancer detection and treatment, with options for refractory disease, including IVIg, rituximab, and emerging therapies like JAK inhibitors. Our case highlights a new association between TIF1α antibodies and tonsil squamous cell carcinoma. Despite successful radiotherapy, cancer recurred. TIF1 antibody detection should prompt rigorous cancer screening, emphasizing multidisciplinary management.


  • Unveiling the Shadow: Unraveling the Cause of Blindness

    by Manush Sondhi, Iman Qaiser, Samina Hayat, Sarwat Umer, Kinza Muzaffar

  • Open Access

    Lung infection or inflammation-a puzzling case of MDA-5 associated juvenile dermatomyositis

    by Anusha Vuppala, Manush Sondhi, Sarwat Umer

    Background: Juvenile dermatomyositis (JDM) is an uncommon inflammatory myopathy predominantly affecting children under 18 years of age. Diagnosis relies on identifying specific clinical features, such as muscle weakness, skin rash, elevated muscle enzymes, and MRI and muscle biopsy findings. Autoantibodies associated with inflammatory myopathy offer valuable prognostic insights and can indicate the risk of internal organ involvement, though they are relatively rare in childhood myopathies. JDM can progress to interstitial lung disease (ILD) if associated with MDA5 antibodies, and immunosuppressive therapy constitutes the primary treatment approach. Case presentation: We present a unique case of JDM complicated by disseminated histoplasmosis in a 12-year-old African American male cross-country runner with no prior medical history. He presented with unintentional weight loss and a rash on his hands, genitals, and fingertips, which persisted despite previous treatments. Diagnosis of JDM was confirmed through clinical and laboratory evaluations. Over time, the patient developed recurrent fevers, thrombocytopenia, and signs of ILD, leading to the identification of disseminated histoplasmosis as a complicating factor. Appropriate antifungal treatment resolved the infectious condition, while continued immunosuppression aided in managing JDM and ILD. Conclusions: Juvenile dermatomyositis (JDM) remains a rare and intricate autoimmune disorder affecting young individuals. The presence of MDA5 antibodies in JDM patients can lead to severe complications like ILD, necessitating vigilant monitoring. Management includes immunosuppressive therapy, with glucocorticoids and mycophenolate mofetil proving effective, particularly in Clinically Amyopathic Dermatomyositis (CADM) cases. In cases of refractory disease, intravenous immunoglobulin (IVIG) plays a crucial role, offering a safe and beneficial adjunct to treatment. We emphasize the importance of recognizing atypical presentations of JDM, as it can lead to delays in diagnosis and treatment. Our case highlights the complexities of managing dual lung pathology, where a secondary infection exacerbated lung nodules and thrombocytopenia, while ILD was a consequence of atypical myopathy. Combining antifungal treatment with immunosuppression effectively managed both conditions and follow-up evaluations demonstrated improvement in ILD. Awareness of potential fungal infections in immunosuppressed JDM patients is crucial for successful treatment and patient outcomes.


  • Sarcoidosis and Worsening Lymphadenopathy: Sarcoidosis Flare? Think Again!

    by Manush Sondhi, Anusha Vuppala, Madiha Tariq

  • Open Access

    Beyond the Acne

    by Manush Sondhi, Warda Maqsood, Sarwat Umer

    Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) is a relatively rare and often underdiagnosed disorder characterized by chronic inflammation affecting the bones, joints, and skin. While the precise cause of SAPHO syndrome remains elusive, multiple factors such as genetics, immunological dysregulation, and bacterial influences have been implicated in its pathogenesis. One notable aspect of SAPHO syndrome is the wide variability of symptoms experienced by afflicted individuals. A diverse array of osteoarticular manifestations may be observed, with common sites of involvement including the anterior chest wall, sacroiliac joints, and peripheral joints. Concurrently, patients often present with various skin disorders, such as palmoplantar pustulosis or acne, further adding to the complexity of the syndrome's clinical presentation. Treatment strategies for SAPHO syndrome primarily focus on managing symptoms and improving the quality of life for affected individuals. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, methotrexate (MTX), and tumor necrosis factor (TNF) inhibitors are considered to modulate the immune response and provide relief. One of the challenges encountered in diagnosing SAPHO syndrome is its potential overlap with other related conditions, leading to diagnostic confusion and difficulties. Distinguishing SAPHO syndrome from similar entities can be complex, requiring a comprehensive evaluation of clinical features, imaging studies, and laboratory investigations. We would like to share an intriguing case involving a 28-year-old woman who arrived with perplexing symptoms of pain in her bilateral hands and feet, her lower back, and acne in the bilateral upper arms and thighs. Through a comprehensive workup, the underlying SAPHO syndrome was uncovered, and it was effectively managed using adalimumab.